Skip to main content
Top
Published in: Cellular Oncology 2/2017

01-04-2017 | Report

ELMO3 expression indicates a poor prognosis in head and neck squamous cell carcinoma - a short report

Authors: Lorenz Kadletz, Gregor Heiduschka, Robert Wiebringhaus, Elisabeth Gurnhofer, Ulana Kotowski, Georg Haymerle, Markus Brunner, Conor Barry, Lukas Kenner

Published in: Cellular Oncology | Issue 2/2017

Login to get access

Abstract

Purpose

Previously, the engulfment and cell motility 3 (ELMO3) protein has been reported to be involved in cell migration and cytoskeletal remodeling. As of yet, nothing is known about the role of ELMO3 in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to asses ELMO3 expression in postoperatively irradiated HNSCC patients and to evaluate a possible correlation between this expression and patient survival.

Methods

125 postoperatively irradiated HNSCC patients were included in this study. ELMO3 expression was assessed using immunohistochemistry (IHC). The expression of ELMO3 in the respective HNSCC tumor tissues and its lymph node metastases was correlated with patient survival using Kaplan-Meier curve analyses.

Results

Through IHC, ELMO3 expression was detected in 71.2% of the HNSCC cases tested. We found significantly increased overall and disease-free survival rates and decreased recurrence rates in patients with no detectable ELMO3 expression. In reverse, we found that ELMO3 expression served as an independent marker for a decreased overall and disease-free survival.

Conclusion

Our data indicate that in the surgically treated and postoperatively irradiated patients tested, ELMO3 expression serves as a predictive marker for reduced survival.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference R.J. Baatenburg de Jong, J. Hermans, J. Molenaar, J.J. Briaire, S. le Cessie, Prediction of survival in patients with head and neck cancer. Head Neck 23, 718–724 (2001)CrossRefPubMed R.J. Baatenburg de Jong, J. Hermans, J. Molenaar, J.J. Briaire, S. le Cessie, Prediction of survival in patients with head and neck cancer. Head Neck 23, 718–724 (2001)CrossRefPubMed
3.
go back to reference D.H. Lee, M.J. Kim, J.L. Roh, S.B. Kim, S.H. Choi, S.Y. Nam, S.Y. Kim, Distant metastases and survival prediction in head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg. 147, 870–875 (2012)CrossRefPubMed D.H. Lee, M.J. Kim, J.L. Roh, S.B. Kim, S.H. Choi, S.Y. Nam, S.Y. Kim, Distant metastases and survival prediction in head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg. 147, 870–875 (2012)CrossRefPubMed
4.
go back to reference E.A. Sisk, S.G. Soltys, S. Zhu, S.G. Fisher, T.E. Carey, C.R. Bradford, Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 24, 841–849 (2002)CrossRefPubMed E.A. Sisk, S.G. Soltys, S. Zhu, S.G. Fisher, T.E. Carey, C.R. Bradford, Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 24, 841–849 (2002)CrossRefPubMed
5.
go back to reference I.P. Ribeiro, F. Caramelo, F. Marques, A. Domingues, M. Mesquitam, L. Barroso, H. Prazeres, M.J. Juliao, I.P. Baptista, A. Ferreira, J. Barbosa Melo, I. Marques Carreira, WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report. Cell. Oncol. 39, 573–558 (2016)CrossRef I.P. Ribeiro, F. Caramelo, F. Marques, A. Domingues, M. Mesquitam, L. Barroso, H. Prazeres, M.J. Juliao, I.P. Baptista, A. Ferreira, J. Barbosa Melo, I. Marques Carreira, WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report. Cell. Oncol. 39, 573–558 (2016)CrossRef
6.
go back to reference B. Jang, J.A. Shin, Y.X. Kim, J.Y. Kim, H.K. Yi, I.S. Park, N.P. Cho, S.D. Cho, Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells. Cell. Oncol. 39, 79–87 (2016)CrossRef B. Jang, J.A. Shin, Y.X. Kim, J.Y. Kim, H.K. Yi, I.S. Park, N.P. Cho, S.D. Cho, Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells. Cell. Oncol. 39, 79–87 (2016)CrossRef
7.
go back to reference Y. You, W. Yng, X. Qi, F. Wang, H. Li, C. Lin, W. Li, C. Gu, Y. Zhang, Y. Ran, CRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. Cell. Oncol. 38, 205–214 (2015)CrossRef Y. You, W. Yng, X. Qi, F. Wang, H. Li, C. Lin, W. Li, C. Gu, Y. Zhang, Y. Ran, CRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. Cell. Oncol. 38, 205–214 (2015)CrossRef
9.
go back to reference M. Patel, T.C. Chiang, V. Tran, F.J.S. Lee, J.F. Cote, The Arf family GTPase Arl4A complexes with ELMO proteins to promote actin cytoskeleton remodeling and reveals a versatile Ras-binding domain in the ELMO proteins family. J. Biol. Chem. 286, 38969–38979 (2011)CrossRefPubMedPubMedCentral M. Patel, T.C. Chiang, V. Tran, F.J.S. Lee, J.F. Cote, The Arf family GTPase Arl4A complexes with ELMO proteins to promote actin cytoskeleton remodeling and reveals a versatile Ras-binding domain in the ELMO proteins family. J. Biol. Chem. 286, 38969–38979 (2011)CrossRefPubMedPubMedCentral
11.
go back to reference S. Søes, I.L. Daugaard, B.S. Sørensen, A. Carus, M. Mattheisen, J. Alsner, J. Overgaard, H. Hager, L.L. Hansen, L.S. Kristensen, Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. Oncoscience 1, 367 (2014)CrossRefPubMedPubMedCentral S. Søes, I.L. Daugaard, B.S. Sørensen, A. Carus, M. Mattheisen, J. Alsner, J. Overgaard, H. Hager, L.L. Hansen, L.S. Kristensen, Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. Oncoscience 1, 367 (2014)CrossRefPubMedPubMedCentral
12.
go back to reference M. Coskun, M. Boyd, J. Olsen, J.T. Troelsen, Control of intestinal promoter activity of the cellular migratory regulator gene ELMO3 by CDX2 and SP1. J. Cell. Biochem. 109, 1118–1128 (2010)PubMed M. Coskun, M. Boyd, J. Olsen, J.T. Troelsen, Control of intestinal promoter activity of the cellular migratory regulator gene ELMO3 by CDX2 and SP1. J. Cell. Biochem. 109, 1118–1128 (2010)PubMed
13.
go back to reference L. Kadletz, J. Bigenzahn, D. Thurnher, I. Stanisz, B.M. Erovic, S. Schneider, R. Schmid, R. Seemann, P. Birner, G. Heiduschka, Evaluation of polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck 38, E1918–E1925 (2015)CrossRefPubMed L. Kadletz, J. Bigenzahn, D. Thurnher, I. Stanisz, B.M. Erovic, S. Schneider, R. Schmid, R. Seemann, P. Birner, G. Heiduschka, Evaluation of polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck 38, E1918–E1925 (2015)CrossRefPubMed
14.
go back to reference G. Heiduschka, A. Grah, F. Oberndorfer, L. Kadletz, G. Altorjai, G. Kornek, F. Wrba, D. Thurnher, E. Selzer, Verbessertes Überleben von HPV/p16-positiven Oropharynxkarzinompatienten mit postoperativer Bestrahlung. Strahlenther. Onkol. 191, 209–216 (2014)CrossRefPubMed G. Heiduschka, A. Grah, F. Oberndorfer, L. Kadletz, G. Altorjai, G. Kornek, F. Wrba, D. Thurnher, E. Selzer, Verbessertes Überleben von HPV/p16-positiven Oropharynxkarzinompatienten mit postoperativer Bestrahlung. Strahlenther. Onkol. 191, 209–216 (2014)CrossRefPubMed
Metadata
Title
ELMO3 expression indicates a poor prognosis in head and neck squamous cell carcinoma - a short report
Authors
Lorenz Kadletz
Gregor Heiduschka
Robert Wiebringhaus
Elisabeth Gurnhofer
Ulana Kotowski
Georg Haymerle
Markus Brunner
Conor Barry
Lukas Kenner
Publication date
01-04-2017
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 2/2017
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0310-8

Other articles of this Issue 2/2017

Cellular Oncology 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine